Disc DegenerationNCT03442374
Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery
A study testing Exercise in people with Disc Degeneration and Low Back Pain, run by University of California, San Diego at 1 site in United States.
Trial summary
Low back pain (LBP) is a complex condition that affects 65-85% of the population, and is the leading musculoskeletal condition contributing to disability in the United States. Disc herniation is the most common injury and 75% of individuals undergoing surgical and rehabilitative interventions for this condition… Read more about this study
- Who is it for?
- Ages 21 to 85 years
- Conditions the study is for
- Disc Degeneration, Low Back Pain
- What is being tested?
- Exercise
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2019to 1 Oct 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Spine pathologies requiring un-instrumented surgery (i.e. laminectomy, laminoforaminotomy, or discectomy).
- Age 21-85 years of age.
Who cannot join
- History of lumbar spine surgery.
- Patients requiring placement of instrumentation as part of the surgical procedure (i.e. fusion).
- Diabetes.
- Neuromuscular diseases.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle
Low back pain (LBP) is a complex condition that affects 65-85% of the population, and is the leading musculoskeletal condition contributing to disability in the United States. Disc herniation is the most common injury and 75% of individuals undergoing surgical and rehabilitative interventions for this condition experience suboptimal or poor outcomes. These patients demonstrate disability and deficits in functional capacity, including strength and endurance of the lumbar musculature. Muscle-specific changes in individuals with LBP include altered muscle volume, fatty infiltration and fibrosis, and fiber area and type. Importantly, these changes are insensitive to rehabilitation in patients with continued chronic or recurrent symptoms. While normal disuse-related atrophy in the presence of LBP is expected, more severe or chronic pathology, such as inflammation and fiber damage, may be inducing irreversible fiber degeneration and fatty/fibrotic tissue changes that impair muscle function and recovery. While the structural and adaptive capacities of healthy muscle are well understood, muscle recovery in the presence of pathology is less clear. To address this gap in knowledge, the purpose of this project is to compare structural, physiological, and adaptive responses of muscle in the presence of acute and chronic lumbar spine pathology. The central hypothesis is that chronic injury results in a state of muscle inflammation, atrophy, fibrosis, and muscle degeneration that is not responsive to exercise. The Investigators will identify which patients respond to exercise by examining muscle hypertrophic, fibrotic, inflammatory, and adipogenic gene expression profiles. Patients will be followed for six months post-operatively to measure muscle recovery and strength.
Read the detailed description
AIM: To determine the effect of exercise on induction of muscle hypertrophic, fibrotic, inflammatory, and adipogenic pathways in patients with mild versus severe fatty infiltration of the multifidus muscle. Rationale. The objectives of this aim are to 1) measure molecular responses of muscle to a well-defined bout of pre-operative exercise, and 2) to determine if baseline morphological or exercise-induced molecular responses predict muscle structural recovery and functional gains up to 6 months post-operatively.
Design. This will be a longitudinal study of 40 patients with mild (< 20%) versus severe (> 50%) fatty infiltration. Non-exercise controls will also be important and the investigators intend to use a portion of biopsied tissue from other experiments as additional controls. Prior to surgery, patients will undergo clinical and MRI examinations. Additionally, patients will undergo an exercise bout 6 hours pre-operatively, and then immediately undergo a short MRI imaging protocol to measure exercise-induced perfusion changes (IVIM). Six hours after the exercise bout, the investigators will collect biopsies of the multifidus during surgery to characterize the hypertrophic, fibrotic, adipogenic, and inflammatory responses. For primary analyses, patient groups will be selected on the basis of severity of muscle fatty infiltration. Group ages and genders will be matched because the investigators know that baseline and exercise-induced gene expression varies with age. Surgical procedure and manipulation of the disc intraoperatively will be documented to account for the potential for disc and other surgery-specific effects on muscle structure. Six months post-operatively, repeated measures of muscle structure will be made via MRI. At 6, 12, and 24 weeks, strength (isokinetic dynamometer) and patient-specific function (questionnaire data) will be obtained as per standard protocol.
Methods:
Physical Examination: A physical therapist with spine injury experience will conduct the clinical exam. Age, gender and body mass index (BMI), duration of symptoms, anti-inflammatory drug use, active and passive range of motion, provocative neural tension tests (measuring joint range of motion [ROM]), strength and endurance as measured on an isokinetic dynamometer (MedX Holdings Inc.), neurovascular status, Oswestry Disability Index (81), Baecke Physical Activity Questionnaire (BPA), Fear Avoidance Beliefs Questionnaire (FABQ), and Pain Catastrophizing Scale (PCS) are important measures that capture both physical and psychosocial factors known to be related to LBP and will be collected at the clinical site. This screen will be used to confirm that discogenic symptoms are isolated to levels below L4, which allows us to use vastus lateralis as an internal control muscle biopsy.
Clinical MRI: Standard axial, sagittal oblique, and coronal oblique MR images of the spine will be collected on all patients who are scheduled for surgery. To identify disc injury severity (Pfirrmann grade), muscle fatty infiltration (Kjaer grade), and to confirm injury location, T1 and T2 non-fat suppressed or contrast-enhanced axial and sagittal MR images of the spine joint will be used.
Multimodal MRI: Imaging will be performed in a single session on a state-of-the-art 3T MRI system (GE MR750). The quantity and distribution of spine muscle volume, fat volume, and connective tissue volume will be performed from supine scans using high-resolution (1mm3) 3D FSPGR, IDEAL fat-water separation, and UTE pulse sequences, respectively using a 32-channel spine array coil. IVIM will be used to quantify regional muscle activation in response to an exercise bout.
Exercise protocol: Prior to surgery, patients will be subjected to a lumbar spine exercise protocol on a MedX Lumbar extension dynamometer with a pelvic restraint system allowing for isolation of lumbar spine muscles. The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension.
Diet protocol: Importantly, the patients will remain NPO (no food or water) after the exercise bout but will have a standardized diet for 24 hours prior to the exercise bout and surgery, which mitigates the effects of diet on gene expression (137, 150-152). Evening meals will be standardized (1900h: 11 kcal/kg; 60% carbohydrate [CHO], 25% fat [FAT], 15% protein [PRO]; 2200h (3 kcal/kg; 95% CHO, 2% FAT, 3% PRO) because meal composition can acutely impact gene and protein expression.
Harvesting and storage of muscle biopsy: Muscle biopsies will be harvested within 6 hours of the exercise bout at their scheduled surgery time. Subjects will be excluded from the analysis if their biopsies are not harvested within 1 hour of the prescribed time point. Biopsies will be obtained with a standard biopsy clamp at the middle and deep margins of the multifidus muscle as noted in Aim #1 and immediately placed in RNAlater (Qiagen) for subsequent qPCR analysis or frozen in liquid nitrogen for protein abundance/phosphorylation measurements.
qPCR and western blotting: Gene expression and protein abundance will be measured by, qPCR and western blotting, respectively. Briefly, real-time PCR will be performed in a Bio-Rad CFX384 using customized plates (PrimePCR, Bio-Rad). Target gene expression will be calculated relative to values from 18S ribosomal subunit, as preliminary findings demonstrate it to be more stable than glyceraldehyde-3-phosphate dehydrogenase (GAPDH; data not presented). For genes in which we find a greater than 3-fold change in expression, western blotting will be used to assess protein abundance, as previously described.
- Conditions
- Disc Degeneration, Low Back Pain
- Being tested
- Exercise
- Keywords
- Multifidus, Muscle, Degeneration, Lumbar Spine, Disc
- Medical subject headings
- Intervertebral Disc Degeneration, Low Back Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExerciseOther
The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
| Study group | Role | What they receive |
|---|---|---|
| Exercise | Experimental | A single bout of moderate intensity lumbar extensor muscle exercise. Receives: Other: Exercise |
| Non-exercise | No intervention | No exercise intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Multifidus Muscle Fatty Infiltration
(% fat at 6 months - % fat at baseline / % fat at baseline)
Measured: 6 months
Secondary outcomes (59)
Change in Oswestry Disability Index (ODI)
Disability Questionnaire (10 questions, % scale is sum of 10 questions/50, higher score is worse), 6 months - baseline
Measured: 6 Months
Change in Fear Avoidance Beliefs Questionnaire (FABQ)
Fear Avoidance Behaviors (sumo 16 items, 0-64 scale, higher score is worse), 6 months- baseline
Measured: 6 months
Change in Pain Catastrophizing Scale (PCS)
Pain behaviors questionnaire (sum of 13 items, 0-52 scale, higher score is worse), 6 months - baseline
Measured: 6 months
Change in Activated Muscle Volume (%)
(% muscle activation after exercise - % muscle activation at baseline / % muscle activation at baseline)
Measured: After exercise (within 5 minutes)
Change in Pain (VAS)
Visual Analog Scale (0-100 mm scale), 6 months - baseline
Measured: 6 months
Change in Strength
MedEx dynamometer, Back Extensor Strength (Nm), 6 months - baseline
Measured: 6 months
MYHC3 gene expression (delta CT/delta CT)
Embryonic myosin heavy chain gene expression
Measured: 6 hours after a single exercise bout
MHY3 protein abundance (ug/mg)
Embryonic myosin heavy chain protein abundance
Measured: 6 hours after a single exercise bout
MYOG gene expression (delta CT/delta CT)
Myogenin gene expression
Measured: 6 hours after a single exercise bout
MYOG protein abundance (ug/mg)
Myogenin protein abundance
Measured: 6 hours after a single exercise bout
PAX7 gene expression (delta CT/delta CT)
PAX7 gene expression
Measured: 6 hours after a single exercise bout
PAX7 gene expression (ug/mg)
PAX7 protein abundance
Measured: 6 hours after a single exercise bout
ANKRD2 gene expression (delta CT/delta CT)
ANKRD2 gene expression
Measured: 6 hours after a single exercise bout
ANKRD2 protein abundance (ug/mg)
ANKRD2 protein abundance
Measured: 6 hours after a single exercise bout
MTOR gene expression (delta CT/delta CT)
MTOR gene expression
Measured: 6 hours after a single exercise bout
MTOR protein abundance (ug/mg)
MTOR protein abundance
Measured: 6 hours after a single exercise bout
COL1A1 gene expression (delta CT/delta CT)
COL1A1 gene expression
Measured: 6 hours after a single exercise bout
COL3A1 gene expression (delta CT/delta CT)
COL3A1 gene expression
Measured: 6 hours after a single exercise bout
COL9A1 gene expression (delta CT/delta CT)
COL9A1 gene expression
Measured: 6 hours after a single exercise bout
LOX gene expression (delta CT/delta CT)
LOX gene expression
Measured: 6 hours after a single exercise bout
CTGF gene expression (delta CT/delta CT)
CTGF gene expression
Measured: 6 hours after a single exercise bout
TGFB1 gene expression (delta CT/delta CT)
TGFB1 gene expression
Measured: 6 hours after a single exercise bout
MMP1 gene expression (delta CT/delta CT)
MMP1 gene expression
Measured: 6 hours after a single exercise bout
MMP3 gene expression (delta CT/delta CT)
MMP3 gene expression
Measured: 6 hours after a single exercise bout
MMP9 gene expression (delta CT/delta CT)
MMP9 gene expression
Measured: 6 hours after a single exercise bout
CEBPA gene expression (delta CT/delta CT)
CEBPA gene expression
Measured: 6 hours after a single exercise bout
FABP4 gene expression (delta CT/delta CT)
FABP4 gene expression
Measured: 6 hours after a single exercise bout
PPARG gene expression (delta CT/delta CT)
PPARG gene expression
Measured: 6 hours after a single exercise bout
PPARD gene expression (delta CT/delta CT)
PPARD gene expression
Measured: 6 hours after a single exercise bout
LEP gene expression (delta CT/delta CT)
LEP gene expression
Measured: 6 hours after a single exercise bout
ADIPOQ gene expression (delta CT/delta CT)
ADIPOQ gene expression
Measured: 6 hours after a single exercise bout
CASP1 gene expression (delta CT/delta CT)
CASP1 gene expression
Measured: 6 hours after a single exercise bout
CASP3 gene expression (delta CT/delta CT)
CASP3 gene expression
Measured: 6 hours after a single exercise bout
TNFa gene expression (delta CT/delta CT)
TNFa gene expression
Measured: 6 hours after a single exercise bout
IL10 gene expression (delta CT/delta CT)
IL10 gene expression
Measured: 6 hours after a single exercise bout
IL6 gene expression (delta CT/delta CT)
IL6 gene expression
Measured: 6 hours after a single exercise bout
IL1B gene expression (delta CT/delta CT)
IL1B gene expression
Measured: 6 hours after a single exercise bout
COL1A1 Protein abundance (ug/mg)
COL1A1 Protein abundance
Measured: 6 hours after a single exercise bout
COL3A1 Protein abundance (ug/mg)
COL3A1 Protein abundance
Measured: 6 hours after a single exercise bout
COL9A1 Protein abundance (ug/mg)
COL9A1 Protein abundance
Measured: 6 hours after a single exercise bout
LOX Protein abundance (ug/mg)
LOX Protein abundance
Measured: 6 hours after a single exercise bout
CTGF Protein abundance (ug/mg)
CTGF Protein abundance
Measured: 6 hours after a single exercise bout
TGFB1 Protein abundance (ug/mg)
TGFB1 Protein abundance
Measured: 6 hours after a single exercise bout
MMP1 Protein abundance (ug/mg)
MMP1 Protein abundance
Measured: 6 hours after a single exercise bout
MMP3 Protein abundance (ug/mg)
MMP3 Protein abundance
Measured: 6 hours after a single exercise bout
MMP9 Protein abundance (ug/mg)
MMP9 Protein abundance
Measured: 6 hours after a single exercise bout
CEBPA Protein abundance (ug/mg)
CEBPA Protein abundance
Measured: 6 hours after a single exercise bout
FABP4 Protein abundance (ug/mg)
FABP4 Protein abundance
Measured: 6 hours after a single exercise bout
PPARG Protein abundance (ug/mg)
PPARG Protein abundance
Measured: 6 hours after a single exercise bout
PPARD Protein abundance (ug/mg)
PPARD Protein abundance
Measured: 6 hours after a single exercise bout
LEP Protein abundance (ug/mg)
LEP Protein abundance
Measured: 6 hours after a single exercise bout
ADIPOQ Protein abundance (ug/mg)
ADIPOQ Protein abundance
Measured: 6 hours after a single exercise bout
CASP1 Protein abundance (ug/mg)
CASP1 Protein abundance
Measured: 6 hours after a single exercise bout
CASP3 Protein abundance (ug/mg)
CASP3 Protein abundance
Measured: 6 hours after a single exercise bout
TNFa Protein abundance (ug/mg)
TNFa Protein abundance
Measured: 6 hours after a single exercise bout
IL10 Protein abundance (ug/mg)
IL10 Protein abundance
Measured: 6 hours after a single exercise bout
IL6 Protein abundance (ug/mg)
IL6 Protein abundance
Measured: 6 hours after a single exercise bout
IL1B Protein abundance (ug/mg)
IL1B Protein abundance
Measured: 6 hours after a single exercise bout
Change in Multifidus muscle volume (%)
Multifidus muscle volume (cc), (6 months - baseline/baseline)
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2018
- Study start1 Jul 2019
- Primary completion1 Jun 2023
- Study completion1 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Disc DegenerationStudies of the same condition, open and under way.
- More trials run by University of California, San DiegoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Stratified by fatty infiltration severity (n=20/group x 2 groups + non exercise controls n=20)
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Diego
- Sponsor type
- University, hospital or other
- Collaborators
- Balgrist University Hospital, Spine Institute of San Diego (Spine Zone)
- Responsible party
- Principal investigator, Samuel R. Ward, University of California, San Diego
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03442374
- Sponsor's protocol ID
- HD088437
- Status last verified
- Nov 2023
- First submitted
- 9 Feb 2018
- Last updated
- 28 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle
- ClinicalTrials.gov ID
- NCT03442374
- Acronym / sponsor ID
- HD088437
- Conditions
- Disc Degeneration, Low Back Pain
- Keywords
- Multifidus, Muscle, Degeneration, Lumbar Spine, Disc
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- University of California, San DiegoUniversity, hospital or other
- Collaborators
- Balgrist University Hospital, Spine Institute of San Diego (Spine Zone)
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 1 Jun 2023 (actual)
- Study completion
- 1 Oct 2023 (actual)
- First posted
- 22 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Low back pain (LBP) is a complex condition that affects 65-85% of the population, and is the leading musculoskeletal condition contributing to disability in the United States. Disc herniation is the most common injury and 75% of individuals undergoing surgical and rehabilitative interventions for this condition experience suboptimal or poor outcomes. These patients demonstrate disability and deficits in functional capacity, including strength and endurance of the lumbar musculature. Muscle-specific changes in individuals with LBP include altered muscle volume, fatty infiltration and fibrosis, and fiber area and type. Importantly, these changes are insensitive to rehabilitation in patients with continued chronic or recurrent symptoms. While normal disuse-related atrophy in the presence of LBP is expected, more severe or chronic pathology, such as inflammation and fiber damage, may be inducing irreversible fiber degeneration and fatty/fibrotic tissue changes that impair muscle function and recovery. While the structural and adaptive capacities of healthy muscle are well understood, muscle recovery in the presence of pathology is less clear. To address this gap in knowledge, the purpose of this project is to compare structural, physiological, and adaptive responses of muscle in the presence of acute and chronic lumbar spine pathology. The central hypothesis is that chronic injury results in a state of muscle inflammation, atrophy, fibrosis, and muscle degeneration that is not responsive to exercise. The Investigators will identify which patients respond to exercise by examining muscle hypertrophic, fibrotic, inflammatory, and adipogenic gene expression profiles. Patients will be followed for six months post-operatively to measure muscle recovery and strength.
Detailed description
AIM: To determine the effect of exercise on induction of muscle hypertrophic, fibrotic, inflammatory, and adipogenic pathways in patients with mild versus severe fatty infiltration of the multifidus muscle. Rationale. The objectives of this aim are to 1) measure molecular responses of muscle to a well-defined bout of pre-operative exercise, and 2) to determine if baseline morphological or exercise-induced molecular responses predict muscle structural recovery and functional gains up to 6 months post-operatively.
Design. This will be a longitudinal study of 40 patients with mild (< 20%) versus severe (> 50%) fatty infiltration. Non-exercise controls will also be important and the investigators intend to use a portion of biopsied tissue from other experiments as additional controls. Prior to surgery, patients will undergo clinical and MRI examinations. Additionally, patients will undergo an exercise bout 6 hours pre-operatively, and then immediately undergo a short MRI imaging protocol to measure exercise-induced perfusion changes (IVIM). Six hours after the exercise bout, the investigators will collect biopsies of the multifidus during surgery to characterize the hypertrophic, fibrotic, adipogenic, and inflammatory responses. For primary analyses, patient groups will be selected on the basis of severity of muscle fatty infiltration. Group ages and genders will be matched because the investigators know that baseline and exercise-induced gene expression varies with age. Surgical procedure and manipulation of the disc intraoperatively will be documented to account for the potential for disc and other surgery-specific effects on muscle structure. Six months post-operatively, repeated measures of muscle structure will be made via MRI. At 6, 12, and 24 weeks, strength (isokinetic dynamometer) and patient-specific function (questionnaire data) will be obtained as per standard protocol.
Methods:
Physical Examination: A physical therapist with spine injury experience will conduct the clinical exam. Age, gender and body mass index (BMI), duration of symptoms, anti-inflammatory drug use, active and passive range of motion, provocative neural tension tests (measuring joint range of motion [ROM]), strength and endurance as measured on an isokinetic dynamometer (MedX Holdings Inc.), neurovascular status, Oswestry Disability Index (81), Baecke Physical Activity Questionnaire (BPA), Fear Avoidance Beliefs Questionnaire (FABQ), and Pain Catastrophizing Scale (PCS) are important measures that capture both physical and psychosocial factors known to be related to LBP and will be collected at the clinical site. This screen will be used to confirm that discogenic symptoms are isolated to levels below L4, which allows us to use vastus lateralis as an internal control muscle biopsy.
Clinical MRI: Standard axial, sagittal oblique, and coronal oblique MR images of the spine will be collected on all patients who are scheduled for surgery. To identify disc injury severity (Pfirrmann grade), muscle fatty infiltration (Kjaer grade), and to confirm injury location, T1 and T2 non-fat suppressed or contrast-enhanced axial and sagittal MR images of the spine joint will be used.
Multimodal MRI: Imaging will be performed in a single session on a state-of-the-art 3T MRI system (GE MR750). The quantity and distribution of spine muscle volume, fat volume, and connective tissue volume will be performed from supine scans using high-resolution (1mm3) 3D FSPGR, IDEAL fat-water separation, and UTE pulse sequences, respectively using a 32-channel spine array coil. IVIM will be used to quantify regional muscle activation in response to an exercise bout.
Exercise protocol: Prior to surgery, patients will be subjected to a lumbar spine exercise protocol on a MedX Lumbar extension dynamometer with a pelvic restraint system allowing for isolation of lumbar spine muscles. The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension.
Diet protocol: Importantly, the patients will remain NPO (no food or water) after the exercise bout but will have a standardized diet for 24 hours prior to the exercise bout and surgery, which mitigates the effects of diet on gene expression (137, 150-152). Evening meals will be standardized (1900h: 11 kcal/kg; 60% carbohydrate [CHO], 25% fat [FAT], 15% protein [PRO]; 2200h (3 kcal/kg; 95% CHO, 2% FAT, 3% PRO) because meal composition can acutely impact gene and protein expression.
Harvesting and storage of muscle biopsy: Muscle biopsies will be harvested within 6 hours of the exercise bout at their scheduled surgery time. Subjects will be excluded from the analysis if their biopsies are not harvested within 1 hour of the prescribed time point. Biopsies will be obtained with a standard biopsy clamp at the middle and deep margins of the multifidus muscle as noted in Aim #1 and immediately placed in RNAlater (Qiagen) for subsequent qPCR analysis or frozen in liquid nitrogen for protein abundance/phosphorylation measurements.
qPCR and western blotting: Gene expression and protein abundance will be measured by, qPCR and western blotting, respectively. Briefly, real-time PCR will be performed in a Bio-Rad CFX384 using customized plates (PrimePCR, Bio-Rad). Target gene expression will be calculated relative to values from 18S ribosomal subunit, as preliminary findings demonstrate it to be more stable than glyceraldehyde-3-phosphate dehydrogenase (GAPDH; data not presented). For genes in which we find a greater than 3-fold change in expression, western blotting will be used to assess protein abundance, as previously described.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Stratified by fatty infiltration severity (n=20/group x 2 groups + non exercise controls n=20)
| Arm | Type | Receives |
|---|---|---|
| Exercise | Experimental | Other: ExerciseA single bout of moderate intensity lumbar extensor muscle exercise. |
| Non-exercise | No intervention | –No exercise intervention. |
Who may qualify
- Ages
- 21 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Spine pathologies requiring un-instrumented surgery (i.e. laminectomy, laminoforaminotomy, or discectomy).
- Age 21-85 years of age.
Key exclusion criteria (4 listed)
- History of lumbar spine surgery.
- Patients requiring placement of instrumentation as part of the surgical procedure (i.e. fusion).
- Diabetes.
- Neuromuscular diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExerciseThe exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension | Other | Exercise |
Primary outcome
Change in Multifidus Muscle Fatty Infiltration
Time frame: 6 months
(% fat at 6 months - % fat at baseline / % fat at baseline)
59 secondary outcomes
Change in Oswestry Disability Index (ODI)
Time frame: 6 Months
Change in Fear Avoidance Beliefs Questionnaire (FABQ)
Time frame: 6 months
Change in Pain Catastrophizing Scale (PCS)
Time frame: 6 months
Change in Activated Muscle Volume (%)
Time frame: After exercise (within 5 minutes)
Change in Pain (VAS)
Time frame: 6 months
Change in Strength
Time frame: 6 months
MYHC3 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
MHY3 protein abundance (ug/mg)
Time frame: 6 hours after a single exercise bout
MYOG gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
MYOG protein abundance (ug/mg)
Time frame: 6 hours after a single exercise bout
PAX7 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
PAX7 gene expression (ug/mg)
Time frame: 6 hours after a single exercise bout
ANKRD2 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
ANKRD2 protein abundance (ug/mg)
Time frame: 6 hours after a single exercise bout
MTOR gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
MTOR protein abundance (ug/mg)
Time frame: 6 hours after a single exercise bout
COL1A1 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
COL3A1 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
COL9A1 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
LOX gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
CTGF gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
TGFB1 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
MMP1 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
MMP3 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
MMP9 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
CEBPA gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
FABP4 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
PPARG gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
PPARD gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
LEP gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
ADIPOQ gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
CASP1 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
CASP3 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
TNFa gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
IL10 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
IL6 gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
IL1B gene expression (delta CT/delta CT)
Time frame: 6 hours after a single exercise bout
COL1A1 Protein abundance (ug/mg)
Time frame: 6 hours after a single exercise bout
COL3A1 Protein abundance (ug/mg)
Time frame: 6 hours after a single exercise bout
COL9A1 Protein abundance (ug/mg)
Time frame: 6 hours after a single exercise bout
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2023.
- Individual participant dataSharing planned: No
Related trials for Disc Degeneration
Not yet recruiting
CANLINK: Evaluation of the Intralink Intradiscal Device for Low Back Pain Due to Degenerative Disc Disease
Degenerative Disc Disease(DDD)
Active, not recruiting
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
Degenerative Disc Disease, Spine Fusion
Not yet recruitingObservational study
Relationship Between Disability, Flexibility, Back Muscles, and Thoracolumbar Fascia in Patients With Lumbar Disc Degeneration
Intervertebral Disc Degeneration
Active, not recruiting
ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs
Degenerative Disc Disease, Disc Degeneration
Active, not recruiting
The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery
Cervical Degenerative Disc Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise in people with Disc Degeneration and Low Back Pain, run by University of California, San Diego at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Multifidus Muscle Fatty Infiltration (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2023.